Resumen de Investigación

Analyzed using Evidence Intelligence™

Ticagrelor monotherapy reduces bleeding in diabetic ACS patients

Última actualización 6 de julio de 2026

Key finding

There was no significant difference in the incidence of MACE between the two groups during 12 months of follow-up.

This study evaluated ticagrelor monotherapy after 3 months of dual antiplatelet therapy in diabetic patients with acute coronary syndrome, finding no significant difference in major adverse cardiovascular events.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

Some Concerns

Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

Clinical relevance

These findings are significant for clinicians managing diabetic patients with acute coronary syndrome, as they suggest that switching to ticagrelor monotherapy may reduce bleeding risks without compromising cardiovascular safety. This could lead to more tailored treatment strategies that balance efficacy and safety.

Keep in mind

The study's sample size and population may limit generalizability. The follow-up period was only 12 months, which may not capture long-term outcomes. Effect sizes were unclear, limiting the strength of conclusions.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Nour EMSI, Mohamed TMZ, Khaled AFAM, Khaled AF, Mina MAI. Ticagrelor Monotherapy After 3 Months of Dual Antiplatelet Treatment in Diabetic Patients with Acute Coronary Syndrome. BMC Cardiovascular Disorders. 2026;26:300. doi:10.1186/s12872-026-05708-w

View DOI View on PubMed View on PMC

Efectos Principales

No significant difference in major adverse cardiovascular events between ticagrelor monotherapy and dual therapy (p-value: null).

Ticagrelor monotherapy was associated with a decrease in overall bleeding events, particularly mild bleeding.

Rates of moderate or severe bleeding were comparable between both treatment groups.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Aspirin, Ticagrelor monotherapy after 3 months of DAPT and Bleeding events, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

This study contributes evidence to

Intervention

Aspirin

Outcome

Bleeding events

Evidence topic

Cardiovascular Risk

Primary intervention

Aspirin

Primary outcomes

Bleeding events
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence topics

Cardiovascular Risk

Primary intervention

Aspirin

Primary outcomes

Bleeding events Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 63

Why it is useful

Contributes to 4 evidence relationships
Includes primary outcome data
Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Tema de evidencia

Cardiovascular Risk

matched_outcome

Core evidence

Study findings

The primary outcomes reported in this study.

Bleeding events

Aspirin → Bleeding events

Evidence Intelligence™

ImpactScore™: 50; Neutral
EvidenceScore™: Emerging; Score 59 · Based on 1 study
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Aspirin → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence Intelligence™

ImpactScore™: 50; Neutral
EvidenceScore™: Emerging; Score 59 · Based on 1 study
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Bleeding events

Ticagrelor monotherapy after 3 months of DAPT → Bleeding events

Evidence Intelligence™

ImpactScore™: 100; Very Positive
EvidenceScore™: Emerging; Score 59 · Based on 1 study
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Ticagrelor monotherapy after 3 months of DAPT → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence Intelligence™

ImpactScore™: 50; Neutral
EvidenceScore™: Emerging; Score 59 · Based on 1 study
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Build your personal Evidence Workspace

Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

La Evidencia Sugiere

No change in major adverse cardiovascular events with ticagrelor monotherapy.
Ticagrelor monotherapy showed a decrease in overall bleeding events.
Moderate or severe bleeding rates were similar in both treatment groups.

A quién se aplica

Diabetic patients diagnosed with acute coronary syndrome.
Patients who have completed at least three months of dual antiplatelet therapy.

Tener en Cuenta

Results may not apply to non-diabetic patients or those with different coronary conditions.
The study did not assess long-term outcomes beyond 12 months.
Further research is needed to confirm findings in larger, diverse populations.

Entre Líneas

The study's sample size and population may limit generalizability.
The follow-up period was only 12 months, which may not capture long-term outcomes.
Effect sizes were unclear, limiting the strength of conclusions.

Save this study

Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Aspirin and Bleeding events, Aspirin and Cardiovascular Outcomes.

Relaciones de evidencia relacionadas

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

Aspirin → Bleeding events

Medications

Evidence Intelligence™

ImpactScore™: 50; Neutral
EvidenceScore™: Emerging; Score 59 · Based on 1 study
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

View evidence

Medications

Detailed evidence

Aspirin → Cardiovascular Outcomes

Medications

Evidence Intelligence™

ImpactScore™: 50; Neutral
EvidenceScore™: Emerging; Score 59 · Based on 1 study
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

Aspirin Evidence Hub

All studies on Aspirin

1 studies

intervention_hub

Contributes to Aspirin evidence base.

Bleeding events Evidence Hub

All studies measuring Bleeding events

1 studies

outcome_hub

Measures Bleeding events as a key outcome.

Cardiovascular Outcomes Evidence Hub

All studies measuring Cardiovascular Outcomes

1 studies

outcome_hub

Measures Cardiovascular Outcomes as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explora más en el archivo de evidencia

Jump to pre-filtered views in the evidence archive.

All studies on Aspirin and Bleeding events

Intervention: AspirinOutcome: Bleeding events

1 results

All studies on Aspirin and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Intervention: AspirinOutcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

1 results

All studies on Aspirin

Intervention: Aspirin

1 results

All studies measuring Bleeding events

Outcome: Bleeding events

1 results

All studies measuring Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Outcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

1 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Ticagrelor monotherapy after 3 months of DAPT improve bleeding events?

Emerging Evidence

Ticagrelor monotherapy after 3 months of DAPT appears to improve Bleeding events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Bleeding events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Aspirin improve bleeding events?

Emerging Evidence

Current evidence does not show a clear benefit of Aspirin for Bleeding events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Bleeding events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Aspirin improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?

Emerging Evidence

Current evidence does not show a clear benefit of Aspirin for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Ticagrelor monotherapy after 3 months of DAPT improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?

Emerging Evidence

Current evidence does not show a clear benefit of Ticagrelor monotherapy after 3 months of DAPT for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Aspirin and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Ticagrelor monotherapy after 3 months of DAPT and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Aspirin and Bleeding events All studies on Ticagrelor monotherapy after 3 months of DAPT and Bleeding events

Related research

Read related research summaries.

HbA1c mediates cardiovascular benefits of GLP-1 receptor agonists Intensive glycemic control may lower cardiovascular events in some diabetes patients Linking Eye Screening Data Improves Understanding of Diabetes Treatments Tighter glycaemic targets may reduce serious infant morbidity Women and frailty linked to poorer adherence in diabetes trial

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.